NCT07430007 Exercise and Dietary Lifestyle Intervention on Reducing Atrial Fibrillation Burden, Cardiac and Body Fat Mass.
| NCT ID | NCT07430007 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Eastern Finland |
| Condition | Atrial Fibrillation (AF) |
| Study Type | INTERVENTIONAL |
| Enrollment | 158 participants |
| Start Date | 2025-10-30 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 158 participants in total. It began in 2025-10-30 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is strongly associated with obesity and excess body fat. Lifestyle interventions, including exercise and dietary modification, may reduce AF burden, but long-term randomized controlled trial evidence with objective AF burden assessment and advanced cardiac imaging is limited. The MOVE-AF trial is a randomized controlled trial designed to evaluate whether a 12-month tailored exercise and dietary lifestyle intervention, compared with usual care, reduces atrial fibrillation burden and symptom severity and decreases cardiac and total body fat mass in overweight and obese adults with paroxysmal or persistent AF.
Eligibility Criteria
Inclusion Criteria: * Age 18-75 years * Body mass index (BMI) ≥27 kg/m² * Documented atrial fibrillation (paroxysmal or persistent) * Ability to participate in exercise training and follow study procedures * Access to a smartphone or device enabling rhythm monitoring * Provides written informed consent Exclusion Criteria: * Permanent atrial fibrillation * Unstable angina pectoris or acute coronary syndrome within the past 3 months * Participation in other lifestyle or drug weight reduction trials * Significant left ventricular dysfunction (ejection fraction \<30%) * Severe valvular heart disease or planned cardiac surgery * Severe heart failure (NYHA class IV) or severe angina (CCS class IV) * Unstable coronary artery disease or recent myocardial infarction * Severe pulmonary disease limiting exercise capacity * Active malignancy * Autoimmune or systemic inflammatory diseases * Severe renal or hepatic failure * Memory disease or significant cognitive impairment * Unstable psychiatric condition * Recent joint or back surgery within the past 6 months * Continuing back or joint pain symptoms and inability to take part in individualized exercise training * Contraindications to exercise testing or training, including cardiac symptoms or cardiovascular symptoms, making exercise unsafe * Pregnancy or breastfeeding * Participation in another interventional study * Any condition judged by investigators to make participation unsafe or infeasible
Contact & Investigator
Jari Laukkanen, MD, PhD
PRINCIPAL INVESTIGATOR
University of Eastern Finland
Frequently Asked Questions
Who can join the NCT07430007 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Atrial Fibrillation (AF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07430007 currently recruiting?
Yes, NCT07430007 is actively recruiting participants. Contact the research team at jariantero.laukkanen@uef.fi for enrollment information.
Where is the NCT07430007 trial being conducted?
This trial is being conducted at Jyväskylä, Finland, Kuopio, Finland, Kuopio, Finland, Tampere, Finland.
Who is sponsoring the NCT07430007 clinical trial?
NCT07430007 is sponsored by University of Eastern Finland. The principal investigator is Jari Laukkanen, MD, PhD at University of Eastern Finland. The trial plans to enroll 158 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.